Medicine Information

Orphan Drugs: Hope Where There Is Little or No Hope


NEW YORK, N.Y., February 18, 2004 - On a visit to his doctor, Gary Jacob received distressing news - not about himself, but a friend of the doctor's.

While playing with one of his children, the doctor's friend fell and broke a rib. That was bad enough, but during the examination at the hospital, the father was hit with a startling and totally unexpected diagnosis - he had a disease known as multiple myeloma, a bone marrow blood cancer.

The diagnosis was nothing less than a death sentence.

Jacob knew of the anguish of multiple myeloma patients. The disease is incurable and nearly always fatal, one of the rare diseases that have few, if any, available treatments. They are known as "orphan" diseases, shunned by most drug-makers because the patient populations are small and commercial development of a drug is seen as economically unattractive.

Mr. Jacob was aware because, as Chief Executive Officer of Callisto Pharmaceuticals, Inc., a small Manhattan-based biopharmaceutical company, he is leading a scientific effort to develop a new orphan drug called "Atiprimod" for multiple myeloma patients.

"The father's disease brought home to me that what we are doing is really important," says Mr. Jacob. "Everyone agrees we need more drugs to treat multiple myeloma. There are people out there dying without real hope because of a lack of effective treatment for all patients."

In steadily increasing numbers, orphan drugs are providing new doses of hope where little or none at all existed. In the decade before the inception of the federal Food and Drug Administration's orphan drug program, 10 drugs were developed by pharmaceutical companies for orphan diseases. In the decades since, the FDA says nearly 250 new drugs were developed and approved, and hundreds more are in the pipeline.

Atiprimod is one of those wending its way toward the marketplace. Callisto recently obtained orphan drug designation from the FDA, providing the company with financial incentives to continue the costly development process.

The program covers drugs for orphan diseases with patient populations under 200,000.

The National Organization for Rare Disorders reports about 25 million people in the United States suffer from an estimated 6,000 orphan diseases.

Diseases such as cystic fibrosis, complications affecting HIV-infected people, Gaucher's disease, hemophilia and rare forms of cancer were among the orphans without effective medicines until the FDA program went into effect in 1983 and paved the way for new drugs for patients with these diseases.

Large drug-makers have been largely missing from the efforts.

According to the orphan drug program's deputy director, Dr. John McCormick, only 15% of applications for orphan drug designation have come from the larger pharmaceutical companies.

The reason: expectations of unfavorable investment returns.

The FDA orphan drug incentives - grants, seven years of marketing exclusivity and tax breaks - have drawn small pharmaceutical companies with promising drug candidates into the breach.

While the future is brighter, the task is still daunting to develop drugs for orphan diseases.

Amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, affects 30,000 Americans with 8,000 new cases diagnosed annually; Huntington's disease also affects about 30,000 patients.

Some diseases affect fewer than 100 patients, according to the National Institutes of Health.

An estimated 50,000 patients have multiple myeloma with 15,000 new patients diagnosed each year. Last year, the FDA approved a new drug Velcade for patients with the disease. However, there are still a number of multiple myeloma patients with no treatment available.

Dr. Kenneth C. Anderson, who played a major role in the preclinical development and clinical trials of Velcade and is now a member of Callisto's Medical Advisory Board, is among the experts who see a need for more drugs to treat multiple myeloma.

"He is excited to see Atiprimod enter clinical trials for evaluation in multiple myeloma patients," Jacob said of Anderson. "He believes it has an opportunity to help patients who have not responded to other drugs. "

Dr. Anderson is director of the Jerome Lipper Multiple Myeloma Center of the Dana-Farber Cancer Institute in Boston, MA, and Professor of Medicine at Harvard Medical School.

The Phase I/IIa trials for Atiprimod are slated to begin later this month.

Dr. Donald Picker, Callisto's Senior Vice President of Drug Development, said studies of Atiprimod in collaboration with scientists at the National Cancer Institute have been very promising.

"In essence, we've shown in these early studies that Atiprimod has the potential to intervene with cancer cells and tumors in three ways - by inhibiting their formation, by programming their death and by limiting their ability to grow blood vessels necessary for their survival. Taken together, these findings suggest that Atiprimod could potentially represent a novel class of compounds for development for therapeutic intervention in human cancers," said Dr. Picker.

About The Author

Alex Michelini is a former award-winning reporter/editor at the New York Daily News. His credits include nomination for a Pulitzer Prize for a series on medical costs. Among his honors, Mr. Michelini received the Deadline Club Award, the Page One Award, the Associated Press Award and the New York Press Club Award (twice). He is the founder of Alex Michelini Public Relations, and has developed and collaborated on articles appearing in the New York Times, the Wall Street Journal, the London Times, the New York Post, the New York Daily News, Bloomberg Radio & TV, CNNfn, WCBS Radio & TV. WINS radio, the Christian Science Monitor, Fox TV, Reuters, Newsday and other media outlets.

michelinialex@aol.com


MORE RESOURCES:
This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news


The Conversation AU

Planned trade deal with Europe could keep medicine prices too high
The Conversation AU
The United States' withdrawal from the Trans Pacific Partnership and the recent US-China tariff wars have flamed concerns that international trade is becoming unstable. Trade talks between Australia and the European Union – Australia's second-largest ...

and more »


Medscape

Marrying or Medicine: Does a White Coat Make Dating Harder?
Medscape
After 4 years of medical school and 2 years of residency, my impression is that love and medicine can be a tricky thing. As a physician, I have dedicated my life to my training. That being said, part of being a human is enjoying the companionship of ...



Symposium supports theme of Women in Medicine Month
Healio
The American Medical Association deems September Women in Medicine Month, when the AMA Women Physicians Section honors physicians who support advancement of women in medical careers. At the Women in Ophthalmology 2018 Summer ...



The BMJ

Seven days in medicine: 12-18 September 2018
The BMJ
Several leading journals including the Lancet and the New England Journal of Medicine are working to correct the record. “It is my hope that this situation will inspire a doubling down on transparency in our field,” he wrote in his resignation letter.

and more »


WVU Medicine Children's marks Familial Hypercholesterolemia Awareness Day to reduce premature heart disease
WVU Medicine (press release)
MORGANTOWN, W.Va. – WVU Medicine Children's is joining organizations across the world to increase awareness of familial hypercholesterolemia (FH) as part of FH Awareness Day on Sept. 24. FH is the most common cause of early heart attacks and ...



WBOY.com

WVU Medicine announces plans to offer heart transplants
WVU Medicine (press release)
MORGANTOWN, W.Va. – WVU Medicine announced today (Sept. 19) its plans to start West Virginia's first heart transplant program at the WVU Heart and Vascular Institute. Gov. Jim Justic (fourth from right) joined WVU Medicine officials at a press Gov.
WVU Medicine to offer heart transplantsWest Virginia MetroNews
WVU Medicine announce first heart transplant programWBOY.com
WVU Medicine to offer heart transplants - Dominion PostThe Dominion Post

all 64 news articles »


The Marc Bulger Foundation donates to WVU Medicine Children's Capital Campaign
WVU Medicine (press release)
“We are proud and excited to present this gift to WVU Medicine Children's,” Bulger said. “As a father myself, it really hits home to see kids who are facing life-threatening illness or injury. They didn't choose to be in that situation. We're happy to ...



Medical Bag

Addressing Ethical Challenges Associated With Precision Medicine
Medical Bag
A precision approach to medical care is the allocation of patients to smaller groups for targeted therapy, with stratification being the primary unifying feature for all precision approaches. In his letter from the editor in the latest issue of the AMA ...



KRVS

Medicine Ball Caravan: September 20, 2018
KRVS
Thursday's MEDICINE BALL CARAVAN on KRVS (11am-noon Central Standard on 88.7FM locally or krvs.org) runs the newest from The Record Company, The Grip Weeds and Zuider Zee. Also: The Chris Leblanc Band cover The Beatles live along with ...



WHAG - www.localdvm.com

National Museum of Civil War Medicine welcomes first 'artist in residence'
WHAG - www.localdvm.com
FREDERICK, Md - About 10 new sculptures have been added to exhibits within the National Museum of Civil War Medicine. Each hand-crafted by Mike Benevenia. "A lot of my work looks like it's broken and it's intentionally supposed to look like that ...


Google News

home | site map | Dr. Thad Thomas
© 2006